Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 61 (9), 265-270

Transfusion Practice in Neonates

Affiliations

Transfusion Practice in Neonates

Do-Hyun Kim. Korean J Pediatr.

Abstract

Neonates, especially extremely low birth weight infants, are among the groups of patients undergoing transfusion frequently. Since they are exposed to higher specific transfusion risks compared to the patients of other age groups, there are many special aspects that must be considered for transfusion therapy in neonates. The transfusion risks in neonates include adverse outcomes specific for preterm infants as well as increased metabolic, immunologic, and infectious complications. To reduce the risks of transfusion-transmitted cytomegalovirus infection and transfusion-associated graft-versus-host disease, leukoreduced and irradiated cellular blood products should be used for all neonates. This review summarizes the risks of neonatal transfusion therapy, specific methods to reduce risk, and current trends and practices of red blood cell and platelet transfusions in neonates, to facilitate decision-making for neonatal transfusion.

Keywords: Neonates; Platelet; Red blood cell; Transfusion.

Conflict of interest statement

No potential conflict of interest relevant to this article was reported.

Similar articles

See all similar articles

References

    1. Maier RF, Sonntag J, Walka MM, Liu G, Metze BC, Obladen M. Changing practices of red blood cell transfusions in infants with birth weights less than 1000 g. J Pediatr. 2000;136:220–4. - PubMed
    1. Fasano RM, Said M, Luban NL. Blood component therapy for the neonate. In: Martin RJ, Fanaroff AV, Walsh MC, editors. Fanaroff and Martin’s neonatal-perinatal medicine: diseases of the fetus and infant. 10th ed. Philadelphia (PA): Elsevier Saunders; 2015. pp. 1344–61.
    1. Goodstein MH, Locke RG, Wlodarczyk D, Goldsmith LS, Rubenstein SD, Herman JH. Comparison of two preservation solutions for erythrocyte transfusions in newborn infants. J Pediatr. 1993;123:783–8. - PubMed
    1. U.S. Food and Drug Administration . Silver Spring (MD): U.S: U.S. Food and Drug Administration; Fatalities reported to FDA following blood collection and transfusion: annual summary for fiscal year 2012 [Internet] [cited 2018 May 15]. Available from: http://www.fda.gov/BiologicsBloodVaccines/SafetyAvailability/ReportaProblem/TransfusionDonationFatalities/ucm346639.htm.
    1. Ohto H, Anderson KC. Posttransfusion graft-versus-host disease in Japanese newborns. Transfusion. 1996;36:117–23. - PubMed
Feedback